Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
NeOnc Technologies Holdings, Inc. ( (NTHI) ) has issued an announcement.
On March 4, 2026, NeOnc Technologies reported Phase 1 dose-escalation results from its Phase 1/2 clinical trial of NEO212, its novel oral bio-conjugated therapy for recurrent glioblastoma and brain metastases. The company said the Maximum Tolerated Dose was reached at 810 mg, establishing 610 mg as the Recommended Phase 2 Dose and 400 mg as the starting dose for the Phase 2a metastasis cohort.
Although the Phase 1 segment was primarily a safety and tolerability study, NeOnc observed early signs of clinical efficacy, including indications of lasting disease control in heavily pretreated patients. Management and external experts described the RP2D determination as a key milestone that de-risks the program, validates the company’s bio-conjugation platform versus standard temozolomide, and enables progression into Phase 2 expansion cohorts in aggressive CNS cancers.
The data mark the first clinical readout of NeOnc’s bioconjugated temozolomide platform in an oral formulation, demonstrating the firm’s capacity to optimize CNS penetration across both intranasal and oral delivery. Supported by a broad patent estate around NEO212 and NEO100, NeOnc views the successful dose confirmation as strengthening its strategic position in CNS oncology and laying groundwork for a potential registrational Phase 2 pathway, subject to regulatory alignment.
The most recent analyst rating on (NTHI) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on NeOnc Technologies Holdings, Inc. stock, see the NTHI Stock Forecast page.
Spark’s Take on NTHI Stock
According to Spark, TipRanks’ AI Analyst, NTHI is a Neutral.
The score is held back primarily by weak financial fundamentals (large losses, negative equity, and heavier cash burn), partially offset by constructive technicals with the stock trading above key moving averages and moderate momentum. Valuation is also a drag due to the negative P/E and lack of dividend yield.
To see Spark’s full report on NTHI stock, click here.
More about NeOnc Technologies Holdings, Inc.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company developing and commercializing central nervous system therapeutics designed to overcome the blood-brain barrier. Its NEO platform has produced novel chemotherapy agents and delivery methods, including NEO100 and NEO212, which are in Phase II trials for malignant gliomas and other CNS cancers, backed by an extensive patent portfolio licensed from the University of Southern California.
The company focuses on proprietary agents such as NEO212, a bio-conjugated oral chemotherapy combining temozolomide with NEO100 to enhance blood-brain barrier penetration and antitumor activity. NeOnc’s programs hold FDA Fast-Track and IND status, with patent protections extending to 2038, positioning the firm in the niche market for differentiated CNS oncology therapies.
Average Trading Volume: 59,862
Technical Sentiment Signal: Hold
Current Market Cap: $214M
For an in-depth examination of NTHI stock, go to TipRanks’ Overview page.